Lonza
Basel, Switzerland
1 confirmed programs
· 1 sponsors
· Last scored 2026-03-04
85.3
Signal Score
○ FDA Inspections
✓ Clinical Trials (1)
○ SEC Filings
✓ Press (20)
Quick Facts: Lonza
- Signal Score
- 85.3/100 (as of 2026-03-04)
- Quality Compliance
- 95.9/100 — No FDA inspection records found for this manufacturer
- Headquarters
- Basel, Switzerland
- Modalities
- AAV, Lentiviral, Cell Therapy, mRNA
- Active Programs
- 1 confirmed from ClinicalTrials.gov across 1 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
95.9
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
1
Sponsors1
ModalitiesAAV, Lentiviral, Cell Therapy, mRNA
1 active programs across 1 sponsors
Modalities: Lentiviral, AAV, Cell Therapy, mRNA
Source: ClinicalTrials.gov facility matching
Source: ClinicalTrials.gov · Retrieved Mar 23, 2026
Financial Stability
75.0
Publicly traded — financial transparency
M&A activity detected (3 articles)
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
M&A activity detected (3 articles)
Capacity
77.0
Multi-site operations (4 manufacturing sites)
Broad modality coverage (4 modalities)
Regulatory milestones (10 articles)
Sites: Houston, TX, Walkersville, MD, Geleen, Netherlands, Portsmouth, NH
Source: SEC EDGAR, press monitoring, company profiles
4 manufacturing sites
Recent Press20 articles
Multi-site operations (4 manufacturing sites)
Broad modality coverage (4 modalities)
Regulatory milestones (10 articles)
Clinical Activity 1 studies
Source: ClinicalTrials.gov · Retrieved Mar 23, 2026
Recent News 20 articles
Lonza Group AG stock under pressure amid Swiss trade surplus data and CDMO transformation momentum - AD HOC NEWS
Lonza Group AG stock under pressure amid Swiss trade surplus data and CDMO transformation momentum AD HOC NEWS
Lonza Group AG stock under pressure on Swiss Exchange amid trade surplus data and CDMO pivot - AD HOC NEWS
Lonza Group AG stock under pressure on Swiss Exchange amid trade surplus data and CDMO pivot AD HOC NEWS
Lonza Group AG stock: Global expansion accelerates with India hub and fermentation market leadership - AD HOC NEWS
Lonza Group AG stock: Global expansion accelerates with India hub and fermentation market leadership AD HOC NEWS
Lonza becomes pure-play CDMO - Speciality Chemicals Magazine
Lonza becomes pure-play CDMO Speciality Chemicals Magazine
Lonza Group AG stock: Global expansion accelerates with India hub and fermentation market leadership - AD HOC NEWS
Lonza Group AG stock: Global expansion accelerates with India hub and fermentation market leadership AD HOC NEWS
Lonza Group AG Stock (ISIN: CH0013841017) Holds Steady Amid Biopharma Sector Volatility - AD HOC NEWS
Lonza Group AG Stock (ISIN: CH0013841017) Holds Steady Amid Biopharma Sector Volatility AD HOC NEWS
Lonza Group AG Stock Faces Headwinds Amid Sector Repricing - AD HOC NEWS
Lonza Group AG Stock Faces Headwinds Amid Sector Repricing AD HOC NEWS
Lonza Group AG Stock Faces Headwinds Amid Sector Repricing - AD HOC NEWS
Lonza Group AG Stock Faces Headwinds Amid Sector Repricing AD HOC NEWS
Lonza Group AG Stock (ISIN: CH0013841017) Faces Biopharma Pressures Amid Sector Shifts - AD HOC NEWS
Lonza Group AG Stock (ISIN: CH0013841017) Faces Biopharma Pressures Amid Sector Shifts AD HOC NEWS
Lonza Group AG Stock (ISIN: CH0013841017) Faces Biopharma Pressures Amid Sector Shifts - AD HOC NEWS
Lonza Group AG Stock (ISIN: CH0013841017) Faces Biopharma Pressures Amid Sector Shifts AD HOC NEWS
Lonza divests Capsules & Health Ingredients business to Lone Star Funds for $3bn - Nutraceutical Business Review
Lonza divests Capsules & Health Ingredients business to Lone Star Funds for $3bn Nutraceutical Business Review
Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia - GEN - Genetic Engineering and Biotechnology News
Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia Genetic Engineering and Biotechnology News
Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO - Indian Pharma Post
Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO Indian Pharma Post
Viral Vector Manufacturing Market Set to Witness Rapid Growth - openPR.com
Viral Vector Manufacturing Market Set to Witness Rapid Growth openPR.com
Lonza Divests Capsules & Health Ingredients Business for $3 Billion - CHEManager
Lonza Divests Capsules & Health Ingredients Business for $3 Billion CHEManager
Lonza, Genetix Bio Extend Commercial Mfg. Pact for ZYNTEGLO - Contract Pharma
Lonza, Genetix Bio Extend Commercial Mfg. Pact for ZYNTEGLO Contract Pharma
Lonza Group - Lonza And Genetix Biotherapeutics Extend Commercial Manufacturing Agreement For Zynteglo - TradingView
Lonza Group - Lonza And Genetix Biotherapeutics Extend Commercial Manufacturing Agreement For Zynteglo TradingView
Lonza Expands Genetix ZYNTEGLO Manufacturing as Gene Therapy Demand Surges - TipRanks
Lonza Expands Genetix ZYNTEGLO Manufacturing as Gene Therapy Demand Surges TipRanks
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO - boerse.de
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO boerse.de
Lonza Sells Its Capsules Unit To Refocus On CDMO Growth - Finimize
Lonza Sells Its Capsules Unit To Refocus On CDMO Growth Finimize
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: